Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

iSpecimen (ISPC) EBT Margin: 2020-2025

Historic EBT Margin for iSpecimen (ISPC) over the last 6 years, with Sep 2025 value amounting to -2,654.92%.

  • iSpecimen's EBT Margin fell 259062.00% to -2,654.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -366.36%, marking a year-over-year decrease of 27309.00%. This contributed to the annual value of -138.39% for FY2024, which is 2915.00% down from last year.
  • Per iSpecimen's latest filing, its EBT Margin stood at -2,654.92% for Q3 2025, which was down 939.70% from -255.36% recorded in Q2 2025.
  • In the past 5 years, iSpecimen's EBT Margin ranged from a high of -57.13% in Q3 2021 and a low of -2,654.92% during Q3 2025.
  • In the last 3 years, iSpecimen's EBT Margin had a median value of -129.89% in 2024 and averaged -383.92%.
  • In the last 5 years, iSpecimen's EBT Margin surged by 13,654bps in 2024 and then slumped by 259,062bps in 2025.
  • iSpecimen's EBT Margin (Quarterly) stood at -79.54% in 2021, then skyrocketed by 662bps to -72.92% in 2022, then crashed by 3,691bps to -109.83% in 2023, then slumped by 29,645bps to -406.28% in 2024, then slumped by 259,062bps to -2,654.92% in 2025.
  • Its last three reported values are -2,654.92% in Q3 2025, -255.36% for Q2 2025, and -154.85% during Q1 2025.